[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 381-400; 401-420; 441-460; 461-480


NICE TAs 421-440



DHFT Formulary link 

East Midlands Cancer Network link (cancer drugs only) 

TA 421                   

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy


TA 422   

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

TA 423  

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens 

TA 424  

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer 

TA 425  

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia 

TA 426      

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia 

TA 427

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib   

TA 428

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

TA 429

Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

TA 430

Sofosbuvir–velpatasvir for treating chronic hepatitis C

TA 431

Mepolizumab for treating severe refractory eosinophilic asthma

Via Regional MDT (Heartlands) for time being

TA 432

Everolimus for advanced renal cell carcinoma after previous treatment

TA 433

Apremilast for treating active psoriatic arthritis

13.5.3 Drugs affecting the immune response 

TA 434

Elotuzumab for previously-treated multiple myeloma (terminated appraisal)

TA 435

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)

TA 436

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)

TA 437

Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)

TA 438

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)

TA 439

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer

TA 440

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine

Not recommended